A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old, following an FDA decision allowing the drug Teplizumab to be used in younger children.
131599
Teplizumab type I diabetes prevention study now enrolls younger children
17878
Genetic accident in sea provides new insight into diabetes:
117212
Rates of severe childhood obesity have tripled
171966
Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
174711
FDA approves obesity drug Belviq
138888
Research could improve cancer treatment
40556
Obese children twice as likely to die young
130150
FDA approves first cord blood product
151436
Girls who lose weight before adulthood lessen risk for diabetes
73557
Obesity drug sails through trials
127
Girls less likely than boys to be on kidney transplant list
72746
Drug originally intended to lower
151845
Fruit and vegetable juice concentrate may improve insulin resistance in overweight boys
110579
Scientists harness new drug discovery tool to treat diabetes
35665
Research associates diabetes with atrial fibrillation
138806
Probiotics may have some benefits for children
93355
Vegetarians have lower risks of diabetes and heart disease